Business Context and Reporting Period
Company: Revelation Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 21, 2026
Reporting Period: Event-based report for January 21, 2026.
The filing discloses a significant regulatory milestone regarding the Company's drug development program for Acute Kidney Injury (AKI).
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material event reported is the Company's agreement with the U.S. Food and Drug Administration (FDA) on the following:
- Approval pathway for the "Gemini" program targeting AKI.
- Design for a single Adaptive Phase 2/3 registration study.
- Confirmation of an approvable composite endpoint.
Additionally, the Company released an updated corporate presentation to the public.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates successful engagement with the FDA, validating the clinical development strategy for the Gemini program. The Company has made a corporate presentation available on its website to detail these developments.
Risks and Contingencies: The filing explicitly states that the information in Item 8.01 and the attached exhibits (Press Release and Corporate Presentation) is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific details of the "Gemini" adaptive Phase 2/3 study design in the attached Press Release (Exhibit 99.1).
- Review the updated Corporate Presentation (Exhibit 99.2) for timelines and resource requirements associated with the new FDA agreement.
- Confirm the definition of the "approvable composite endpoint" for AKI as agreed upon with the FDA.
- Monitor future filings for the initiation of the Phase 2/3 study and any subsequent financial impact on cash burn or funding needs.